Literature DB >> 22626885

A benefit/risk approach towards selecting appropriate pharmaceutical dosage forms - an application for paediatric dosage form selection.

Tom Sam1, Terry B Ernest, Jennifer Walsh, Julie L Williams.   

Abstract

The design and selection of new pharmaceutical dosage forms involves the careful consideration and balancing of a quality target product profile against technical challenges and development feasibility. Paediatric dosage forms present particular complexity due to the diverse patient population, patient compliance challenges and safety considerations of this vulnerable population. This paper presents a structured framework for assessing the comparative benefits and risks of different pharmaceutical design options against pre-determined criteria relating to (1) efficacy, (2) safety and (3) patient access. This benefit/risk framework has then been applied to three hypothetical, but realistic, scenarios for paediatric dosage forms in order to explore its utility in guiding dosage form design and formulation selection. The approach allows a rigorous, systematic and qualitative assessment of the merits and disadvantages of each dosage form option and helps identify mitigating strategies to modify risk. The application of a weighting and scoring system to the criteria depending on the specific case could further refine the analysis and aid decision-making. In this paper, one case study is scored for illustrative purposes. However, it is acknowledged that in real development scenarios, the generation of actual data considering the very specific situation for the patient/product/developer would come into play to drive decisions on the most appropriate dosage form strategy.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22626885     DOI: 10.1016/j.ijpharm.2012.05.024

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  11 in total

Review 1.  Formulations for children: problems and solutions.

Authors:  Hannah K Batchelor; John F Marriott
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

2.  Development and evaluation of an assessment of the age-appropriateness/inappropriateness of formulations used in children.

Authors:  Jennifer C Duncan; Louise E Bracken; Anthony J Nunn; Matthew Peak; Mark A Turner
Journal:  Int J Clin Pharm       Date:  2022-10-08

3.  Chronic Medication Use and Factors Associated With Polypharmacy Among Outpatient Pediatric Patients.

Authors:  Celeste L Y Ewig; Kai Sang Wong; Pak Hei Chan; Ting Fan Leung; Yin Ting Cheung
Journal:  J Pediatr Pharmacol Ther       Date:  2022-08-19

4.  A chewable pediatric preparation of ibuprofen is palatable and acceptable to children.

Authors:  Steven Barnett; Aomesh Bhatt
Journal:  Paediatr Neonatal Pain       Date:  2020-02-10

5.  Solid oral forms availability in children: a cost saving investigation.

Authors:  Audrey Lajoinie; Emilie Henin; Behrouz Kassai; David Terry
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

Review 6.  Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms.

Authors:  Felipe L Lopez; Terry B Ernest; Catherine Tuleu; Mine Orlu Gul
Journal:  Expert Opin Drug Deliv       Date:  2015-07-13       Impact factor: 6.648

7.  A Focus Group Study about Oral Drug Administration Practices at Hospital Wards-Aspects to Consider in Drug Development of Age-Appropriate Formulations for Children.

Authors:  Maria Rautamo; Kirsi Kvarnström; Mia Sivén; Marja Airaksinen; Pekka Lahdenne; Niklas Sandler
Journal:  Pharmaceutics       Date:  2020-01-30       Impact factor: 6.321

8.  Oral medicines for children in the European paediatric investigation plans.

Authors:  Diana A van Riet-Nales; Erwin G A W Römkens; Agnes Saint-Raymond; Piotr Kozarewicz; Alfred F A M Schobben; Toine C G Egberts; Carin M A Rademaker
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

Review 9.  Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects.

Authors:  Diana A van Riet-Nales; Alfred F A M Schobben; Herman Vromans; Toine C G Egberts; Carin M A Rademaker
Journal:  Arch Dis Child       Date:  2016-03-15       Impact factor: 3.791

10.  Assessing the Appropriateness of Formulations on the WHO Model List of Essential Medicines for Children: Development of a Paediatric Quality Target Product Profile Tool.

Authors:  Jennifer Walsh; Tiziana Masini; Benedikt D Huttner; Lorenzo Moja; Martina Penazzato; Bernadette Cappello
Journal:  Pharmaceutics       Date:  2022-02-22       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.